Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | CCKAR | P32238 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.32 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12743611 | 1.00 | GLP1R (0.46) | GLP1RMEN1KMT2AALBRECQL | |
| SCHEMBL14685800 | 0.93 | GLP1R (0.46) | GLP1RALBFAAHTSHR | |
| SCHEMBL14685801 | 0.93 | GLP1R (0.48) | GLP1RMEN1KMT2AALBRECQL | |
| SCHEMBL8115663 | 0.90 | GLP1R (0.51) | GLP1RMEN1KMT2AALBTSHR | |
| SCHEMBL17401199 | 0.90 | GLP1R (0.46) | GLP1RMEN1KMT2AALBRECQL | |
| SCHEMBL14685783 | 0.89 | GLP1R (0.54) | GLP1RMEN1KMT2ARECQLFAAH | |
| SCHEMBL27342812 | 0.88 | GLP1R (0.61) | GLP1RCCKARCCKBRC3AR1 | |
| SCHEMBL13539399 | 0.87 | GLP1R (0.46) | GLP1RMEN1KMT2AALBTSHR | |
| SCHEMBL14725960 | 0.87 | GLP1R (0.46) | GLP1RMEN1KMT2ARECQLFAAH | |
| SCHEMBL24372267 | 0.85 | MEN1 (0.57) | MEN1KMT2AALBRECQLTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK A/S (DK) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLP1R, GIPR, GCGR | GLP1R 1/4885MEN1 2368/4885KMT2A 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.